Published: December 07, 2015

Dr. Kim Chi, Co-Chair of Canadian Cancer Trials Group's Genitourinary Site Committee and medical oncologist at the British Columbia Cancer Agency in Vancouver, has been awarded $500,000 from the Canadian Cancer Clinical Trials Network (3CTN) for the support of an exciting new IND Program suite of trials in castrate resistant prostate cancer, "Precision Oncology Platform for Prostate Cancer: A Phase 2 Umbrella Trial for Patients with Metastatic Castration Resistant Prostate Cancer."

Published: November 18, 2015

You are invited to join the Canadian Cancer Society’s exclusive Telephone Town Hall, where a panel of experts will bring the world of clinical trials to life and explain how clinical trials are improving cancer prevention, detection and treatment.

Published: November 03, 2015

Dr. Ming Tsao, Chair of Canadian Cancer Trials Group's Correlative Sciences Tumour Biology Committee, was recently presented with the Mary J. Matthews Pathology/Translational Research Award at the 16th World Conference on Lung Cancer.

Published: October 19, 2015

Results of Canadian Cancer Trials Group SC.23 show that dexamethasone lowers the rate of pain flare in cancer patients with bone metastases undergoing radiation therapy for symptom control.

Published: October 09, 2015
On September 19, the Canadian Cancer Trials Group Trialblazers Run a Muck team participated in the Kingston Canadian Cancer Society Mudmoiselle and raised more than $2000 -- far surpassing their goal of $600!!
Published: October 09, 2014

The first results from the TAILORx Trial – MAC.12 – just published in the New England Journal of Medicine, are part of the larger Canadian Cancer Trials Group MAC.12 (ECOG PACCT-1) trial – Program for Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment (TAILORx). This study was designed to further validate and refine the clinical usefulness of the 21-gene assay (Oncotype DX Recurrence Score, Genomic Health) in women with hormone-receptor–positive, HER2-negative, axillary node-negative invasive breast cancer.

Published: October 19, 2015

Recent studies show promising results with the use of enzalutamide in patients who have metastatic prostate cancer that has progressed while on ADT, whether it is given before or after chemotherapy. Enzalutamide, in both settings, as compared with placebo, significantly extended survival with delays in disease progression, improved patient-reported quality of life and had a favourable adverse event profile.

Published: July 24, 2015

Research conducted by Canadian Cancer Trials Group at Queen’s University has provided new information regarding the use of radiotherapy in the treatment of breast cancer.